The Challenge of Defining Alzheimer Disease Based on Biomarkers in the Absence of Symptoms

Teresa Gomez-Isla^{1

2}, Matthew P Frosch^{2

3}

Affiliations

¹ Department of Neurology, Massachusetts General Hospital, Boston.
² Massachusetts Alzheimer's Disease Research Center, Boston.
³ C. S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, Boston.

Teresa Gomez-Isla et al. JAMA Neurol. 2019.

. 2019 Oct 1;76(10):1143-1144.

doi: 10.1001/jamaneurol.2019.1667.

Teresa Gomez-Isla^{1

2}, Matthew P Frosch^{2

3}

¹ Department of Neurology, Massachusetts General Hospital, Boston.
² Massachusetts Alzheimer's Disease Research Center, Boston.
³ C. S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, Boston.

No abstract available

Comment in

Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging-Alzheimer's Association Research Framework.
Jack CR Jr, Therneau TM, Weigand SD, Wiste HJ, Knopman DS, Vemuri P, Lowe VJ, Mielke MM, Roberts RO, Machulda MM, Graff-Radford J, Jones DT, Schwarz CG, Gunter JL, Senjem ML, Rocca WA, Petersen RC. Jack CR Jr, et al. JAMA Neurol. 2019 Oct 1;76(10):1174-1183. doi: 10.1001/jamaneurol.2019.1971. JAMA Neurol. 2019. PMID: 31305929 Free PMC article.